M.Success FX is Not Associated with Equiti UK, FCA Warns

Another clone firm has come up on the radar of the (FCA), as the regulator has published a warning against M.Success FX, which it claims is a clone firm of Equiti Capital UK Limited.
Equiti Capital is a multi-asset execution-only brokerage, located in the United Kingdom. The firm is authorised and licensed by the FCA, with the following firm reference number – 528328.

Taking a look at the clone firm’s website (https://www.m-successfx.com/en/col.jsp?id=101) M.Success FX claims to be part of the mace group, which apparently has offices across Asia, Europe and North America. On its “About Us” page, the entity claims that Equiti(mace UK) is part of the mace group. 
Clarifying the relationship between Equiti and M.Success FX, the FCA states: “This FCA authorised firm that fraudsters are claiming to work for has no association with the ‘clone firm’. It is authorised to offer, promote or sell services or products in the UK.”
On its website, the entity also claims: “ Its liquidity is fully regulated by the UK’s FCA (foreign exchange transaction regulatory license). It has more than 200,000 individual and institutional clients worldwide, with millions of transactions each month. He has never left any bad record and is praised by regulators and investors as the most trustworthy and excellent dealer.”
However, given today’s warning, it is clear that M.Success FX is not regulated by the FCA whatsoever, so any other claims made on its website can be assumed as false.
FCA Continues to Flag Clone Firms
As the name suggests, clone firms are fraudulent entities which copy details of a legitimate firm, such as their name, website, address, registration details, etc. Some even go to the lengths of completely copying a firm – from their website, to brand, in order to trick investors into thinking that they are the actual legitimate firm.
Clone firms are a big problem in the foreign exchange (forex) and cryptocurrency sectors. As , Tickmill, and , among others, have all been targeted by clone firms.

Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *